In a mouse model, the administration of IL6 decreased Th2 cytokines and ameliorates asthma.28 In patients, tocilizumab, an anti-IL6 signaling therapy, has been associated with some adverse events including skin rashes and eczema.29 This evidence concerns the gene IL6 and exanthem.